Organogenesis Holdings Stock Debt To Equity

ORGO Stock

USD 3.90 0.06 1.52%

Organogenesis Holdings fundamentals help investors to digest information that contributes to Organogenesis Holdings' financial success or failures. It also enables traders to predict the movement of Organogenesis Stock. The fundamental analysis module provides a way to measure Organogenesis Holdings' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Organogenesis Holdings stock.

		Last Reported	Projected for Next Year
	Debt To Equity	0.29	0.30

As of the 28th of November 2024, Debt To Equity is likely to grow to 0.30.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Organogenesis Holdings Company Debt To Equity Analysis

Organogenesis Holdings' Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.

D/E

Total Debt

Total Equity

More About Debt To Equity | All Equity Analysis

Current Organogenesis Holdings Debt To Equity

0.52 %

Most of Organogenesis Holdings' fundamental indicators, such as Debt To Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Organogenesis Holdings is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Organogenesis Debt To Equity Driver Correlations

Understanding the fundamental principles of building solid financial models for Organogenesis Holdings is extremely important. It helps to project a fair market value of Organogenesis Stock properly, considering its historical fundamentals such as Debt To Equity. Since Organogenesis Holdings' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Organogenesis Holdings' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Organogenesis Holdings' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Retained Earnings	Accounts Payable	Long Term Debt	Net Receivables	Good Will	Short Term Investments	Total Liab	Deferred Long Term Liab	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock	Property Plant Equipment	Net Debt	Capital Surpluse	Net Invested Capital	Net Working Capital	Current Deferred Revenue	Long Term Debt Total	Capital Stock
Total Assets		0.92	0.73	-0.34	0.84	0.16	0.86	0.85	0.43	0.8	0.67	0.82	0.72	0.64	0.26	0.7	0.41	0.8	0.1	0.82	0.39	0.57	0.79
Total Stockholder Equity	0.92		0.54	-0.04	0.62	0.24	0.65	0.64	0.38	0.51	0.6	0.55	0.53	0.51	0.57	0.58	0.12	0.51	0.29	0.59	0.42	0.31	0.59
Net Tangible Assets	0.73	0.54		-0.26	0.74	-0.1	0.87	0.69	0.28	0.8	0.87	0.87	0.95	0.34	-0.34	0.89	0.39	0.83	0.22	0.92	0.5	0.64	0.95
Retained Earnings	-0.34	-0.04	-0.26		-0.54	0.16	-0.38	-0.63	-0.09	-0.7	0.13	-0.55	-0.33	-0.6	0.29	-0.1	-0.73	-0.66	0.79	-0.44	0.47	-0.64	-0.34
Accounts Payable	0.84	0.62	0.74	-0.54		0.35	0.93	0.93	0.61	0.91	0.65	0.9	0.72	0.72	-0.14	0.78	0.65	0.9	-0.1	0.87	0.25	0.77	0.79
Long Term Debt	0.16	0.24	-0.1	0.16	0.35		0.15	0.15	0.65	-0.02	0.22	-0.02	-0.09	0.33	0.32	0.28	-0.03	-0.06	0.16	0.02	-0.04	0.18	-0.03
Net Receivables	0.86	0.65	0.87	-0.38	0.93	0.15		0.86	0.52	0.91	0.79	0.96	0.82	0.59	-0.22	0.83	0.48	0.93	0.13	0.96	0.46	0.63	0.91
Good Will	0.85	0.64	0.69	-0.63	0.93	0.15	0.86		0.5	0.89	0.55	0.85	0.74	0.84	-0.05	0.67	0.63	0.89	-0.24	0.8	0.18	0.67	0.76
Short Term Investments	0.43	0.38	0.28	-0.09	0.61	0.65	0.52	0.5		0.36	0.48	0.39	0.37	0.42	0.04	0.59	0.2	0.41	0.06	0.37	0.34	0.28	0.42
Total Liab	0.8	0.51	0.8	-0.7	0.91	-0.02	0.91	0.89	0.36		0.55	0.97	0.78	0.62	-0.31	0.66	0.72	0.98	-0.22	0.92	0.21	0.79	0.83
Deferred Long Term Liab	0.67	0.6	0.87	0.13	0.65	0.22	0.79	0.55	0.48	0.55		0.66	0.83	0.3	-0.14	0.94	0.18	0.59	0.47	0.74	0.7	0.39	0.8
Total Current Assets	0.82	0.55	0.87	-0.55	0.9	-0.02	0.96	0.85	0.39	0.97	0.66		0.83	0.55	-0.33	0.73	0.55	0.98	0.0	0.98	0.33	0.73	0.92
Short Term Debt	0.72	0.53	0.95	-0.33	0.72	-0.09	0.82	0.74	0.37	0.78	0.83	0.83		0.48	-0.3	0.87	0.37	0.82	0.09	0.86	0.42	0.59	0.93
Intangible Assets	0.64	0.51	0.34	-0.6	0.72	0.33	0.59	0.84	0.42	0.62	0.3	0.55	0.48		0.15	0.41	0.44	0.6	-0.39	0.49	-0.15	0.39	0.44
Common Stock	0.26	0.57	-0.34	0.29	-0.14	0.32	-0.22	-0.05	0.04	-0.31	-0.14	-0.33	-0.3	0.15		-0.19	-0.3	-0.33	0.14	-0.31	-0.03	-0.28	-0.29
Property Plant Equipment	0.7	0.58	0.89	-0.1	0.78	0.28	0.83	0.67	0.59	0.66	0.94	0.73	0.87	0.41	-0.19		0.31	0.7	0.28	0.8	0.51	0.57	0.86
Net Debt	0.41	0.12	0.39	-0.73	0.65	-0.03	0.48	0.63	0.2	0.72	0.18	0.55	0.37	0.44	-0.3	0.31		0.63	-0.64	0.44	0.0	0.67	0.3
Capital Surpluse	0.8	0.51	0.83	-0.66	0.9	-0.06	0.93	0.89	0.41	0.98	0.59	0.98	0.82	0.6	-0.33	0.7	0.63		-0.15	0.94	0.25	0.74	0.89
Net Invested Capital	0.1	0.29	0.22	0.79	-0.1	0.16	0.13	-0.24	0.06	-0.22	0.47	0.0	0.09	-0.39	0.14	0.28	-0.64	-0.15		0.14	0.62	-0.23	0.22
Net Working Capital	0.82	0.59	0.92	-0.44	0.87	0.02	0.96	0.8	0.37	0.92	0.74	0.98	0.86	0.49	-0.31	0.8	0.44	0.94	0.14		0.37	0.73	0.96
Current Deferred Revenue	0.39	0.42	0.5	0.47	0.25	-0.04	0.46	0.18	0.34	0.21	0.7	0.33	0.42	-0.15	-0.03	0.51	0.0	0.25	0.62	0.37		-0.06	0.42
Long Term Debt Total	0.57	0.31	0.64	-0.64	0.77	0.18	0.63	0.67	0.28	0.79	0.39	0.73	0.59	0.39	-0.28	0.57	0.67	0.74	-0.23	0.73	-0.06		0.65
Capital Stock	0.79	0.59	0.95	-0.34	0.79	-0.03	0.91	0.76	0.42	0.83	0.8	0.92	0.93	0.44	-0.29	0.86	0.3	0.89	0.22	0.96	0.42	0.65

Click cells to compare fundamentals

High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.

Competition

Predict Organogenesis Holdings

Debt To Equity Over Time

Organogenesis Total Stockholder Equity

Total Stockholder Equity

179.42 Million

At this time, Organogenesis Holdings' Total Stockholder Equity is very stable compared to the past year.

According to the company disclosure, Organogenesis Holdings has a Debt To Equity of 0.517%. This is 99.03% lower than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The debt to equity for all United States stocks is 98.94% higher than that of the company.

Organogenesis Debt To Equity Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Organogenesis Holdings' direct or indirect competition against its Debt To Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Organogenesis Holdings could also be used in its relative valuation, which is a method of valuing Organogenesis Holdings by comparing valuation metrics of similar companies.

Organogenesis Holdings is currently under evaluation in debt to equity category among its peers.

Organogenesis Holdings Current Valuation Drivers

We derive many important indicators used in calculating different scores of Organogenesis Holdings from analyzing Organogenesis Holdings' financial statements. These drivers represent accounts that assess Organogenesis Holdings' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Organogenesis Holdings' important valuation drivers and their relationship over time.

	2019	2020	2021	2022	2023	2024 (projected)
Market Cap	446.6M	811.3M	1.2B	349.9M	536.7M	726.0M
Enterprise Value	487.0M	811.6M	1.2B	371.2M	551.7M	744.2M

Organogenesis Holdings ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Organogenesis Holdings' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Organogenesis Holdings' managers, analysts, and investors.

Environmental

Governance

Social

Organogenesis Fundamentals

	Return On Equity	-0.0266
	Return On Asset	0.0164
	Profit Margin	(0.02) %
	Operating Margin	0.05 %
	Current Valuation	538.33 M
	Shares Outstanding	132.58 M
	Shares Owned By Insiders	43.44 %
	Shares Owned By Institutions	48.28 %
	Number Of Shares Shorted	10.41 M
	Price To Earning	17.12 X
	Price To Book	1.88 X
	Price To Sales	1.14 X
	Revenue	433.14 M
	Gross Profit	345.87 M
	EBITDA	36.03 M
	Net Income	4.95 M
	Cash And Equivalents	113.24 M
	Cash Per Share	0.87 X
	Total Debt	119.35 M
	Debt To Equity	0.52 %
	Current Ratio	2.62 X
	Book Value Per Share	2.10 X
	Cash Flow From Operations	30.92 M
	Short Ratio	19.97 X
	Earnings Per Share	(0.05) X
	Price To Earnings To Growth	6.15 X
	Target Price	4.7
	Number Of Employees	862
	Beta	1.6
	Market Capitalization	517.05 M
	Total Asset	460.02 M
	Retained Earnings	(40.97 M)
	Working Capital	144.53 M
	Current Asset	24.47 M
	Current Liabilities	23.22 M
	Net Asset	460.02 M

About Organogenesis Holdings Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Organogenesis Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Organogenesis Holdings using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Organogenesis Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Pair Trading with Organogenesis Holdings

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Organogenesis Holdings position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Organogenesis Holdings will appreciate offsetting losses from the drop in the long position's value.

Moving together with Organogenesis Stock

0.84

BMY

Bristol Myers Squibb Aggressive Push

Pair Corr

Moving against Organogenesis Stock

0.84	PEPG	PepGen	Pair Corr
0.82	JNJ	Johnson Johnson Fiscal Year End 28th of January 2025	Pair Corr
0.76	MRK	Merck Company Fiscal Year End 6th of February 2025	Pair Corr
0.76	NKTX	Nkarta Inc Buyout Trend	Pair Corr
0.73	MREO	Mereo BioPharma Group	Pair Corr

The ability to find closely correlated positions to Organogenesis Holdings could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Organogenesis Holdings when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Organogenesis Holdings - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Organogenesis Holdings to buy it.

The correlation of Organogenesis Holdings is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Organogenesis Holdings moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Organogenesis Holdings moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Organogenesis Holdings can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Organogenesis Holdings offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Organogenesis Holdings' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Organogenesis Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Organogenesis Holdings Stock:

How To Invest In Organogenesis

Details

Is Organogenesis Stock a good investment?

Details

What is Organogenesis Holdings' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Organogenesis Holdings Piotroski F Score and Organogenesis Holdings Altman Z Score analysis.

To learn how to invest in Organogenesis Stock, please use our How to Invest in Organogenesis Holdings guide.

You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Organogenesis Holdings. If investors know Organogenesis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Organogenesis Holdings listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

3.5

Earnings Share

(0.05)

Revenue Per Share

3.446

Quarterly Revenue Growth

0.061

Return On Assets

0.0164

The market value of Organogenesis Holdings is measured differently than its book value, which is the value of Organogenesis that is recorded on the company's balance sheet. Investors also form their own opinion of Organogenesis Holdings' value that differs from its market value or its book value, called intrinsic value, which is Organogenesis Holdings' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Organogenesis Holdings' market value can be influenced by many factors that don't directly affect Organogenesis Holdings' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Organogenesis Holdings' value and its price as these two are different measures arrived at by different means. Investors typically determine if Organogenesis Holdings is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Organogenesis Holdings' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Organogenesis Holdings Stock Debt To Equity

Organogenesis Holdings Company Debt To Equity Analysis

D/E

Total Debt

Total Equity

Current Organogenesis Holdings Debt To Equity

Organogenesis Debt To Equity Driver Correlations

Organogenesis Total Stockholder Equity

Total Stockholder Equity

179.42 Million

Organogenesis Debt To Equity Peer Comparison

Organogenesis Holdings Current Valuation Drivers

Organogenesis Holdings ESG Sustainability

Organogenesis Fundamentals

About Organogenesis Holdings Fundamental Analysis

Pair Trading with Organogenesis Holdings

Moving together with Organogenesis Stock

Moving against Organogenesis Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY